Document:

exv10w25

Exhibit 10.25

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.

Execution Copy

LICENSE AGREEMENT

This License Agreement (the “Agreement”), effective as of December 10, 2008 (“Effective Date”),
between Cosmo Technologies Limited, a company duly incorporated and existing under the laws of
Ireland, with registered offices at 4243 Amiens Street, Dublin 1, Ireland (“Licensor”) and
Santarus, Inc. a company duly incorporated and existing under the Laws of Delaware, USA, with
offices at 3721 Valley Centre Drive, Suite 400, San Diego, California 92130 USA (“Licensee”).

WHEREAS, Licensor possesses certain intellectual property rights (the “Patents”, “Know-How” and
“Trademarks” as hereinafter defined) related to the Products (as hereinafter defined);

WHEREAS, Licensee possesses capabilities in marketing, development and commercialization of
pharmaceutical products in the “Territory” (as hereinafter defined);

WHEREAS, Licensee desires to engage in development, marketing and sale of the Products;

WHEREAS, Licensee desires to acquire from Licensor, and Licensor is willing to grant to Licensee,
an Exclusive (as hereinafter defined) license under Licensor’s Patents, Know-How and Trademarks
relating to the Products in the Territory (as hereinafter defined);

WHEREAS, Licensor is a fully owned subsidiary of Cosmo Pharmaceuticals S.p.A., a company duly
incorporated under the laws of Italy, with registered offices in Lainate (Milan), Via Cristoforo
Colombo 1 (“Cosmo”); and

WHEREAS, Licensee has conducted a due diligence procedure on the Patents.

NOW, THEREFORE, the Parties agree and stipulate as follows:

	1	 	Definitions.

1

 

	 	1.1	 	“Affiliate” means, with respect to each Party hereto, any corporation, company, firm,
partnership, joint venture and/or other entity that controls, or is controlled by, or is
under common control with, such Party. For purposes of this Section 1.1, the term
“control” means, in the case of corporate entities, direct or indirect ownership of at
least fifty percent (50%) of the stock or shares having the right to vote for the election
of directors (other than such ownership by an employee benefit plan (or related trust)
sponsored or maintained by a Party) and, in the case of non-corporate entities, direct or
indirect ownership of at least fifty percent (50%) of the equity interest with the power
to direct the management and policies of such non-corporate entities.
	 
	 	1.2	 	“Agreement” means this license agreement.
	 
	 	1.3	 	“Applicable Laws” means any and all federal, state or local law, statute or
ordinance, or any rule, regulation, or published guidelines promulgated by any
governmental or Regulatory Authority which are applicable to the use, manufacture, import,
export, marketing, distribution and/or sale of Products, including the United States Food,
Drug and Cosmetic Act and applicable regulations promulgated thereunder, as they may be
amended or supplemented from time to time, or any equivalent successor or foreign laws or
regulations.
	 
	 	1.4	 	“Exclusive” means in respect of a right granted under this Agreement the grantor will
not exercise that right and has not and will not authorize others to exercise that right.
	 
	 	1.5	 	“FDA” means the United States Food and Drug Administration or its successor agencies
in the Territory.
	 
	 	1.6	 	“First Commercial Sale” means the date of the first commercial sale of a Product
approved by a Regulatory Authority in the Territory by Licensee or its Affiliate to a
third party.
	 
	 	1.7	 	“Improvements” means any invention, discovery, development, enhancement, alteration
or modification to the Product, whether or not patented or patentable.
	 
	 	1.8	 	“GAAP” means generally accepted accounting principles in the United States,
consistently applied.

2

 

	 	1.9	 	“Know-How” means any and all information, data and materials relating to Products
known by Licensor but not generally known or available, which information, data and
materials are necessary or useful in order to develop, market, use, distribute, import,
export, offer to sell or sell (but not produce or manufacture) Products in accordance with
this Agreement.
	 
	 	1.10	 	“LIBOR” means the London Inter Bank Offered Rate as quoted each day at 1600 GMT.
	 
	 	1.11	 	“Milestone Event” means the event that triggers the payment of a milestone, according
to section 3.
	 
	 	1.12	 	“NDA” means a new drug application submitted to the FDA for approval to market,
distribute and sell a pharmaceutical product in the Territory.
	 
	 	1.13	 	“NDA Acceptance” means the date on which the FDA or other Regulatory Authority
accepts for filing Licensee’s application for Regulatory Approval for the applicable
Product.
	 
	 	1.14	 	“Net Sales” means, with respect to the applicable period, the amount billed or
invoiced by Licensee or its Affiliates to customers or unrelated third parties for each
Product, less all allowances for discounts, rebates, charge-backs, which are reasonable
and in good commercial practice, allowances for Product returns actually credited to third
parties due to defective or expired Product, taxes and similar customary deductions, as
calculated in accordance with Licensee’s standard accounting principles and GAAP and
reported in Licensee’s filings with the Securities and Exchange Commission.
	 
	 	1.15	 	“Orange Book” means the listing published by the FDA that specifies patent rights
applicable to approved drug products, which is available electronically at
http://www.fda.gov/cder/ob/.
	 
	 	1.16	 	“Party” means either Licensor or Licensee and “Parties” shall mean both Licensor and
Licensee, collectively.
	 
	 	1.17	 	“Patents” means:
	 
	 	 	 	as for Product A as hereinafter defined: (a) International Application WO/2000/76478,
US App. No. 10/009,532 titled

3

 

	 	 	 	“Controlled Release And Taste Masking Oral Pharmaceutical Compositions”, US App. No.
11, 268/500 titled “Controlled Release And Taste Masking Oral Pharmaceutical
Compositions”, and related applications thereof, including all other provisional and
other patent applications that Licensor, Cosmo Pharmaceuticals SpA or respective
Affiliates own or control, as of the Effective Date, or at any time during the term
of this Agreement in the Territory related to making, using, or selling or offering to
sell (but not, for the purpose of this Agreement, producing or manufacturing), Product
A, or that claim or cover the Product, including the patents listed on Schedule A
hereto; (b) all patent applications filed either from such patent applications or
provisional applications or from an application claiming priority from either of
these, including divisionals, continuations, continuations-in-part, provisionals,
converted provisionals, continued prosecution applications including, but not limited
to, US App. No 12/210,969, (c) any and all patents that have issued or in the future
issue from the foregoing patent applications, including utility, model and design
patents and certificates of invention, including, but not limited to, US Patent No.
7,410,651 titled “Controlled release and taste masking oral pharmaceutical
compositions”, US Patent No. 7.431,943 titled “Controlled release and taste masking
oral pharmaceutical compositions”, (d) any and all extensions or restorations by
existing or future extension or restoration mechanisms, including substitutions,
revalidations, reissues, renewals, re-examinations, extensions (including any
supplementary protection certificates and the like), or any confirmation patent or
registration patent or patent additions to any such foregoing patent applications and
patents and (e) the inventions claimed or covered therein, for the sole part
pertaining to Product A. The patents and patent applications listed in Schedule A
shall inter alia be included in the term “Patents A”;
	 
	 	 	 	as for Product B as hereinafter defined: (a) International Application WO/2000/76478,
International Application WO/2006/003043, US App. No. 10/009,532 titled “Controlled
Release And Taste Masking Oral Pharmaceutical Compositions”, US Patent Application No.
11/571,044 titled “Oral Antimicrobial Pharmaceutical Compositions”, and related
applications thereof, including provisional and other patent applications that
Licensor, Cosmo Pharmaceuticals SpA or their respective Affiliates, own or control,
as of the Effective Date, or at any time during the term of this Agreement in the
Territory related to making, using, or selling or offering to sell (but not, for the
purpose of this Agreement,

4

 

	 	 	 	producing or manufacturing) Product B, or that claim or cover the Product, including
the patents listed on Schedule B hereto, (b) all patent applications filed either from
such patent applications or provisional applications or from an application claiming
priority from either of these, including divisionals, continuations,
continuations-in-part, provisionals, converted provisionals, continued prosecution
applications, (c) any and all patents that have issued or in the future issue from the
foregoing patent applications, including utility, model and design patents and
certificates of invention, including, but not limited to, US Patent No. 7,431,943
titled “Controlled Release And Taste Masking Oral Pharmaceutical Compositions”,
(d) any and all extensions or restorations by existing or future extension or
restoration mechanisms, including substitutions, revalidations, reissues, renewals,
re-examinations, extensions (including any supplementary protection certificates and
the like), or any confirmation patent or registration patent or patent additions to
any such foregoing patent applications and patents and (e) the inventions claimed or
covered therein, for the sole part pertaining to Products B. The patents and patent
applications listed in Schedule B shall inter alia be included in the term “Patents
B”.

	 	1.18	 	“Products” means the following Licensors’ proprietary pharmaceutical products:
	 
	 	 	 	Product A: any oral formulation product containing Budesonide or other
anti-inflammatory corticosteroids as an active ingredient, formulated with a
multi-matrix (MMX) drug releasing technology, for the treatment of patients with
Ulcerative Colitis and all other human uses;
	 
	 	 	 	Product B: any oral formulation product containing Rifamycin SV as an active
ingredient, formulated with a multi-matrix (MMX) drug releasing technology, for the
treatment of patients with Travellers Diarrhoea and all other human uses.
	 
	 	1.19	 	“Promotional Costs” means all costs and expenditures associated with the marketing,
promotion and sale of the Products in the Territory, including, without limitation,
advertising, agency fees, materials, medical affairs, meetings and, when not specifically
excluded, allocated sales force costs.
	 
	 	1.20	 	“Regulatory Approval” means with respect to a Product or any Improvements thereto,
any approval required under Applicable

5

 

	 	 	 	Law in any jurisdiction in the Territory to exploit such Product or Improvements
thereto in accordance with the licenses granted to Licensee hereunder.

	 	1.21	 	“Regulatory Authority” means the FDA and any similar governmental authority,
administrative agency or commission of any country, state, county, city or other political
subdivision in the Territory.
	 
	 	1.22	 	“Royalty Term” means, on a Product by Product basis, the period of time from the
Effective Date through the date upon which the last Valid Claim for the applicable Product
expires.
	 
	 	1.23	 	“Share Price” shall mean the price equal to the average daily closing price of
Licensee’s common stock, reported by the NASDAQ Global Market for the thirty consecutive
trading days ending on the day immediately prior to the achievement of the applicable
Milestone Event.
	 
	 	1.24	 	“Successful Conclusion” means: (a) with
respect to Product A, [***] and (b) with respect to Product B, [***].
	 
	 	1.25	 	“Territory” means the United States and all of its territories and possessions,
including, but not limited to, Puerto Rico.
	 
	 	1.26	 	“Third Party Agreements” means the agreements Licensor has currently entered into
with ICON Clinical, NMB Limited and Datatrak International Limited or any other such
agreement Licensor and Licensee shall mutually agree to enter into for the scope of
Product Regulatory Approval.
	 
	 	1.27	 	“Trademarks” means the trademarks listed in Schedule C.
	 
	 	1.28	 	“Valid Claim” means either (a) a claim of an issued and unexpired patent or a
supplementary protection certificate within the Patents with respect to Product A or
Product B, as applicable, that has not been held permanently revoked, unenforceable, or
invalid by a decision of a court or other governmental authority of competent
jurisdiction, unappealable or unappealed within the time allowed for appeal and that is
not admitted to be invalid or unenforceable

 

			
	***	 	Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

6

 

	 	 	 	through reissue, disclaimer, or otherwise (i.e., only to the extent the subject matter
is disclaimed or is sought to be deleted or amended through reissue), or (b) a claim
of a pending patent application within the Patents with respect to Product A or
Product B, as applicable, that has not been abandoned, finally rejected, or expired
without the possibility of appeal or refiling; provided, however, that “Valid Claim”
shall exclude any such pending claim in an application that has not been granted
within [***] years following the earliest priority filing
date for such application (unless and until such claim is granted).

	2	 	License Grants.

	 	2.1	 	Licensor grants, and Licensee accepts, upon the terms set forth in this
Agreement, an Exclusive, irrevocable right and license in the Territory, under the
Patents and the Know-How, to develop, market, use, distribute, import, export, offer to
sell and sell (but not produce or manufacture) the Products and any Improvements
thereto.
	 
	 	2.2	 	Licensor grants, and Licensee accepts, upon the terms set forth in this
Agreement, an Exclusive, irrevocable license to use the Trademarks to develop, market,
use, distribute, import, export, offer to sell and sell the Products and any
Improvements in the Territory.
	 
	 	2.3	 	Licensee is not entitled to sublicense the rights granted in this Section 2
without the prior written consent of Licensor.
	 
	 	2.4	 	The license is limited to the oral formulations of:

a) as for what pertains Product A, product containing budesonide or other
anti-inflammatory corticosteroids as an active ingredient;

b) as for what pertains Product B, product containing Rifamycin SV as an active
ingredient.

 

			
	***	 	Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

7

 

No license is given, neither express or implied, for the use of the Patents for, or
in connection with, any other active ingredient or for any other different product
other than the Products and any Improvements.

	 	2.5	 	Licensor, in addition, reserves the right to use the Patents for research
purposes, publish or otherwise disseminate any information about the Patents, provided
that any research of the Products in the Territory shall be coordinated between the
Parties. Diffusion of new information on the Products (including research papers,
scientific posters, clinical trial data) shall be coordinated between the Parties.

	3	 	Fees and Payments.

	 	3.1	 	In consideration for the rights and license granted by Licensor to Licensee herein,
Licensee agrees to make the following payments to Licensor:

	 	3.1.1	 	Up-front Payments at signing of this Agreement:

a) as for what pertains Product A, 5.000.000 (five million) newly
issued shares of Licensee’s common stock;

b) as for what pertains Product B, 1.000.000 (one million) newly
issued shares of Licensee’s common stock plus USD 2.500.000 (two
million five hundred thousand dollars);

Licensee shall be obliged to fully register the resale of such shares, deliver them in physical form in the name of Licensor and
have the registration statement declared effective within 123 days
from the Effective Date.

The payment of the amount of USD 2.500.000 (two million five hundred
thousand dollars) shall be executed by means of wire transfer within
3 working days from the Effective Date to the account designated by
Licensor.

	 	3.1.2	 	Regulatory Milestones

8

 

as for what pertains Product A

[***]

as for what pertains Product B

[***]

	 	3.1.3	 	Commercial Milestones

as for what pertains Product A

[***]

as for what pertains Product B

[***]

These Commercial Milestones shall be added by Licensor to each
royalty invoice following overtaking of the threshold.

	 	3.1.4	 	At the election of Licensor (such election to be made
within 30 (thirty) days from the receipt by Licensor of notice that a
Milestone Event has occurred), each Regulatory Milestone and Commercial
Milestone shall be paid in newly issued shares of Licensee’s common stock.
Such shares shall be issued to Licensor at the Share Price within the
following 10 working days from Licensor’s election. The amount of shares
issued shall be calculated by dividing the Regulatory Milestone or
Commercial Milestone due by the Share Price and rounded to the lower full
share amount with the fraction paid in cash.

Licensee shall not be obliged to issue shares to Licensor at the
occurrence of a Milestone Event if either:

 

			
	***	 	Certain information on this page has been omitted and filed
separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.

9

 

a) the aggregate number of shares issued to Licensor (including the shares issued as Up-front Payment), as a result of cumulative
election by Licensor, shall exceed 10.300.000 (ten million three
hundred thousand) shares.

or

b) such issuance could reduce the amount of the Licensee’s
accumulated net operating losses deductible for tax purposes against
future earnings (Internal Revenue Code Section 382) in excess of USD
[***] ([***] dollars) as determined by Licensee. In order for such
limitation to apply, Licensee shall share, upon request by Licensor,
relevant information on situation of net operating losses deductible
for tax purposes against future earnings. In the event Licensor
disagrees with Licensee’s assessment, Licensee shall engage an
appropriate outside auditor to conduct an assessment, the cost of
which shall be shared equally by the Parties.

The counter value of the shares which can not be issued due to either
a) or b) shall be paid in cash to Licensor within 10 (ten) working
days after receipt by Licensee of Licensor’s election. Licensee shall
pay all its bank charges resulting from the execution of such
milestone payments.

All executional issues regarding issuance and registration of shares
according to this provision shall be governed by the Stock Issuance
Agreement and Registration Rights Agreement between the Parties
annexed to the Agreement as Schedule D and E.

	 	3.2	 	As additional consideration for the rights and licenses granted by Licensor to
Licensee herein, Licensee agrees:

As for Product A

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

10

 

	 	3.2.1	 	to pay a portion (as hereinafter provided) of direct third party
costs of clinical trials and registration costs paid by Licensor (“Direct Costs”)
before or after the Effective Date under Third Party Agreements necessary to
achieve Regulatory Approval for Product A. Licensee in this respect acknowledges
that Licensor has already undertaken certain obligations under the Third Party
Agreements for phase III clinical trials of Product A and that such clinical
trials design assumes that the relevant data shall be collected both from
European and North-American countries, for the simultaneous use towards both FDA
and EMEA for the scope of Regulatory Approval for Product A. Licensee accepts
therefore under this section to reimburse Licensor 50% of all phase III clinical
trials Direct Costs. In this respect and additionally, on or before January 31,
2009 and subject to Licensee receiving an invoice therefore, Licensee shall
reimburse Licensor EUR 1.617.500 and USD 737.124 (equal to 50% of phase III
clinical trial Direct Costs already borne for the current phase III clinical
trials for Product A, amounting to, as of November 18, 2008, to EUR 3.235.000 and
USD 1.474.248). Subsequent costs shall be reimbursed accordingly by Licensee to
Licensor in the same proportion on a monthly basis within 30 (thirty) days
following an invoice from Licensor, which shall be provided within 10 (ten) days
following month’s end. If clinical work is required to obtain Regulatory Approval
to market Product A in addition to that specifically contemplated in the Third
Party Agreements, the Parties shall agree on the additional work to be performed
and on an equitable division of the costs therefore, consistent with the equal
division of expenses set forth under this section 3.2.1.

As for Product B

	 	3.2.2	 	to pay the costs of one phase III clinical trial and registration
costs necessary to achieve Regulatory Approval for Product B, provided that
Licensor and/or its licensee in the EU shall be responsible for conducting a
second phase III clinical trial in the same indication. If clinical work is
required to obtain Regulatory Approval to market Product B in addition to the two
contemplated pivotal phase III clinical studies, the Parties shall agree on the
additional work to be performed and on an equitable division of the costs
therefore, consistent

11

 

	 	 	 	with the division of expenses set forth under this section 3.2.2. If, for
whatever reason, additional pre-clinical studies should be required, Licensor
shall be in charge of them at its own expense. 

	 	 	 	For clarity, for both Products Licensor shall be responsible for all costs
associated with manufacturing scale-up, stability studies and other Product
development activities required for filing of the Regulatory Approvals or
required by any Regulatory Authority.

	 	3.3	 	As additional consideration for the rights and licenses granted by Licensor to
Licensee herein, subject to Sections 3.4 and 3.5. during the Royalty Term, Licensee
agrees to pay to Licensor:

As for what pertains Product A:

(i) a royalty of 12% (twelve percent) on annual Net Sales in the Territory [***]; and

(ii) a royalty of 14% (fourteen percent) on annual Net Sales in the Territory
[***].

As for what pertains Product B:

(i) a royalty of 12% (twelve percent) on annual Net Sales in the Territory [***]; and

(ii) a royalty of 14% (fourteen percent) on annual Net Sales in the Territory [***].

	 	3.4	 	The royalties may be reduced at any time prior to the expiry of the last Valid
Claim with respect to a Product in the Territory to account for any and all royalties or
other payments paid by Licensee to any third party, under (a) any license that would be
necessary for Licensee to resolve any claims that the Product infringes or
misappropriates the intellectual property rights of any third party; or (b) any final
judgment awarded against Licensee for damages for infringement of third party
intellectual property rights consistent with the foregoing sub-section (a). Licensee
shall

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

12

 

	 	 	 	use commercially reasonable efforts to minimize any such royalties or other payments
to third parties on account of sales of Product hereunder. The reduction shall not
exceed an amount equal to 50% of the royalty payable to Licensor according to section
3.3.

	 	3.5	 	If, at any time during the term of this Agreement, there is a Competitive Product
(as defined below) being sold in the Territory, then beginning with the calendar quarter
immediately following the calendar quarter during which a product became a Competitive
Product, the royalty rate shall be set with respect to Net Sales of such Product in the
Territory at fifty percent (50%) of the applicable royalty rate set forth in Section 3.3
until such time as there is no Competitive Product in the Territory. For purposes of
this Section 3.5, “Competitive Product” shall mean a product or products that are
AB-rated generic versions of a Product.
	 
	 	3.6	 	As additional consideration for the rights and license granted by Licensor to
Licensee herein, Licensee agrees to enter into a supply agreement with Licensor and/or
one of its Affiliates, as Licensor shall designate, and/or third party supplier approved
by Licensee (the “Supplier”) for the manufacture and supply of the Products, which shall
include the terms and conditions set forth under section 5 of this Agreement.

	4	 	Reports, Records and Payments.

	 	4.1	 	After First Commercial Sale of each Product anywhere in the Territory, Licensee
shall submit to Licensor quarterly royalty reports for each Product on or before 45 days
after the end of each calendar quarter ending March 31, June 30 and September 30 and 75
days after the end of last quarter of each year. Each royalty report shall cover
Licensee’s most recently completed calendar quarter and shall show the gross sales,
itemized deductions as provided in Paragraph 1.14, and Net Sales of each Product during
the most recently completed calendar quarter and the royalties, in USD, payable with
respect thereto. Each such report shall be accompanied by a payment equal to the total
royalties or Commercial Milestones owed by Licensee with respect to such previous
calendar quarter in accordance with the terms of section 3.

13

 

	 	4.2	 	Licensee shall keep accurate and correct records of all Products sold. Such
records shall be retained by Licensee for at least 5 (five) years following a given
reporting period.
	 
	 	4.3	 	All relevant records shall be available during normal business hours for
inspection at the expense of Licensor by a certified public accountant selected by
Licensor and in compliance with the other terms of this Agreement for the sole purpose
of verifying reports and payments. Such inspections shall occur no more than once per
calendar year and Licensor shall provide at least thirty (30) days written notice prior
to such an inspection. Such inspector shall not disclose to Licensor any information
other than information relating to the accuracy of reports and payments made under this
Agreement or other compliance issues. In the event that any such inspection shows an
under reporting and underpayment in excess of five percent (5%) for any twelve (12)
month period, then Licensee shall pay the cost of the audit as well as any additional
sum that would have been payable to Licensor had the Licensee reported correctly, plus
an interest charge at a rate of LIBOR [***]. Such interest shall
be calculated from the date the correct payment was due to Licensor up to the date when
such payment is actually made by Licensee. For an underpayment not in excess of five
percent (5%) for any twelve (12) month period, Licensee shall pay the difference within
thirty (30) days without inspection cost charge but with interest charge of LIBOR [***].
With respect to any overpayment, Licensor shall credit the amount of such overpayment
against any future amounts owed by Licensee pursuant to this Agreement, or if no further
payments are due by Licensee hereunder, Licensor shall promptly refund the full amount
of the overpayment to Licensee.
	 
	 	4.4	 	All cash fees and royalties due to Licensor shall be paid in USD. All payments
due to Licensor shall be made by electronic transfer (wire-transfer) to the account that
Licensor shall timely communicate to Licensee.

	 	4.5	 	Royalties earned on sales occurring pursuant to this Agreement shall not be
reduced by Licensee for any taxes, fees, or other charges imposed by the government on
the payment of fee and royalty income, except that all payments made by Licensee in

 

			
	***	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.

14

 

	 	 	 	fulfilment of Licensor’s tax liability in any particular country may be credited
against earned royalties or fees due to Licensor for that country. For the avoidance
of doubt, if there is a royalty paid to Licensor subject to a withholding tax imposed
on Licensor, Licensee is entitled to reduce royalties by such amount required to be
remitted to a government on behalf of Licensor. Licensee shall pay all its bank
charges resulting from the execution of such royalty payments.
	 
	 	4.6	 	In the event royalty, reimbursement and/or fee payments are not received by
Licensor when due, Licensee shall pay to Licensor interest charges at a rate of LIBOR
[***]. Such interest shall be calculated from the date
payment was due until actually received by Licensor.

	5	 	Supply.

	 	5.1	 	Following Effective Date and no later than the date of the first NDA submission,
the Parties shall enter into a definitive manufacturing and supply agreement containing
the terms set forth in this section 5, together with all other customary and reasonable
terms, pursuant to which Supplier shall manufacture and supply for and on behalf of
Licensee, and Licensee shall purchase supplies of Products (the “Supply Agreement”). In
the event the Parties do not finalize such Supply Agreement, the supply of Products
between the Parties shall be governed by the following sections.
	 
	 	5.2	 	During the term of this Agreement, Licensee shall purchase its requirements of
Products exclusively from Supplier and Supplier shall manufacture and supply Licensee’s
needs of Products exclusively to Licensee in the Territory.
	 
	 	5.3	 	All deliveries of Products shall be made to Licensee EXW Cosmo SpA, via Colombo
1, 20020 Lainate (MI) Italy (Incoterms 2000) in bulk form. Risk in and responsibility
for any consignment of Products shall pass on to Licensee once such consignment has been
loaded on Licensee’s vehicle at Cosmo SpA storage (or at such other location as Licensor
may notify in advance to Licensee).

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

15

 

	 	5.4	 	Licensee shall obtain any necessary import licenses, certificates of origin or
other requisite documents, and pay all applicable customs, duties and taxes in respect
of the importation of the Products into the Territory and their sale in the Territory.
	 
	 	5.5	 	Licensor represents and warrants that all Products manufactured and supplied to
Licensee under the Supply Agreement: (a) shall have been manufactured, packaged, tested
and stored in compliance with the specifications, cGMP, Applicable Laws and the terms
and conditions of the Supply Agreement; (b) shall not be adulterated, or misbranded, as
defined under Applicable Laws, as of the time that the Product is delivered to Licensee
in accordance with the terms of the Supply Agreement; and (c) shall have a to-be agreed
minimum shelf life at the time of delivery. Licensee’s prior written consent shall be
required in connection with any proposed change to the specifications or manufacturing
process.
	 
	 	5.6	 	Licensor shall take and store samples from each production batch of the Product
for the period of time required by Applicable Laws.
	 
	 	5.7	 	Licensor warrants that, on the date of shipment, the Products will conform to the
specifications in this Agreement set forth in Schedule F. Licensee shall notify Licensor
of any alleged non-conforming Product or quantity discrepancies within thirty (30) days
of its receipt thereof, except that notification of latent defects shall be within
thirty (30) days of their discovery by Licensee. Licensor shall replace any
non-conforming Product, without cost to Licensee.

	 	5.8	 	Licensee shall provide Supplier an 18-month rolling forecast for each Product and
the first three months of such forecast shall be binding on Licensee and cannot be
amended by greater than [***]% ([***] percent) without the consent
of Supplier. Licensee shall update the 18-month forecast monthly. Licensee shall issue
to Supplier orders for Products at least ninety (90) days before the requested delivery
date, which order shall be consistent with the binding portion of the 18-month forecast
as described above,

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

16

 

	 	 	 	unless otherwise agreed by the Parties. For orders in excess of the 18-month rolling
forecast as described above, Supplier shall make reasonable efforts to supply such
excess amount.

	 	5.9	 	The Parties agree that Licensee shall purchase Products from Supplier [***]. Price shall include the cost for the Active
Pharmaceutical Ingredient (API), which shall be borne by Licensor. The Parties agree
that this price is set with reference to Products in a fully finished and packaged form.
Should Licensee opt to take responsibility for packaging from bulk form to fully
finished and packaged form, the associated costs reasonably borne by Licensee shall be
deducted from the price. Samples required for commercialisation shall be supplied by
Supplier at actual cost of goods.
	 
	 	5.10	 	[***] Reasonably in advance of First Commercial Sale, and reasonably in advance of
each year ending December 31 thereafter, Licensee and Supplier shall agree on a price per
tablet of Product which, upon the available information at that point in time, shall
reflect the principles set forth in Section 5.9.
	 
	 	5.11	 	Prior to the initial shipment of Product under the Supply Agreement, the Parties
shall negotiate in good faith and enter into a quality agreement to further define the
roles and responsibilities for the manufacture (including the packaging), quality control,
release, and shipment of the Product.
	 
	 	5.12	 	The Parties will co-operate in relation to any voluntary or involuntary recall or
other withdrawal of a Product. When either Party anticipates that a recall or other
withdrawal may be necessary, such Party shall notify and consult with the other as soon
as it has notice of the reasons for such recall, such notification to be given within 24
hours, provided that Licensee shall have the ultimate decision-making authority with
respect to all matters relating to the recall of any Product. Supplier shall be liable
for and shall indemnify Licensee against all reasonable costs incurred by Licensee in
implementing a recall of a Product where and to the extent such recall is caused by a
breach by Licensor of any representation, warranty or covenant of the Supply Agreement,
and further, at Licensee’s election, Supplier shall

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

17

 

	 	 	 	either (i) replace the volume of recalled Product as soon as reasonably practicable, but in no
event later than ninety (90) days after the date of the recall, or (ii) reimburse Licensee
in an amount equal to the amount paid by Licensee for the recalled Product, together with
all out-of-pocket expenses related thereto.
	 
	 	5.13	 	Supplier agrees to provide access to back-up suppliers for Licensee in the event of a
supply failure.

	6	 	Licensee’s Marketing Efforts.

	 	6.1	 	Licensee shall use commercially reasonable efforts to market, promote and sell
the Products in the Territory at its own cost. At least one year prior to the initial
launch of each Product in the Territory, the DMC described in Section 6.7 shall meet to
share marketing and promotional information on the launch. For the sake of this section,
“commercially reasonable efforts” shall be evaluated with reference to the class of
products to which each Product pertains and shall mean a level of effort consistent with
that applied by Licensee, or comparable peer companies, for other products with similar
potential and sufficient to meet the target timelines specified in section 6.3, subject
to the assumptions set out therein. In any case, Licensee shall expend or commit to
expend [***]:

	 
	 	 	 	As for Product A

	 	a)	 	[***]
	 
	 	b)	 	[***]
	 
	 	c)	 	[***]

	 	 	 	As for Product B

	 	a)	 	[***]
	 
	 	b)	 	[***]
	 
	 	c)	 	[***]

	 	 	 	Licensee further undertakes to utilize at least [***] sales representatives to
promote each Product (which may be the same [***]) during the first year of sales of
each Product and a

 

			
	***	 	Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

18

 

	 	 	 	commercially reasonable number of sales representatives thereafter.

	 	6.2	 	Licensee shall use commercially reasonable efforts to obtain reimbursement for
each of the Products in the Territory at its own cost.
	 
	 	6.3	 	Licensee shall launch and market each Product in the Territory within 12 (twelve)
months of Licensee receiving Regulatory Approval to market such product in the
Territory, subject at all times to Supplier’s timely performance of its obligations
under the Supply Agreement.
	 
	 	6.4	 	Without the other Party’s prior written consent, neither Party shall have the
right, directly or indirectly, to develop, promote or market, or appoint or grant the
right to any third party to promote or market in the Territory other products which
contain as an active ingredient:
	 
	 	 	 	As for Product A
	 
	 	 	 	anti-inflammatory corticosteroids for Ulcerative Colitis and such other indications as
may be approved for Product A; and
	 
	 	 	 	As for Product B
	 
	 	 	 	antibiotics belonging to the ansamycin family for Travellers Diarrhoea and such other
indications as may be approved for Product B.
	 
	 	6.5	 	Licensee shall use commercially reasonable efforts to fill market demand for each
Product following commencement of marketing at any time during the term of this
Agreement, subject at all times to Supplier’s timely performance of its obligations
under the Supply Agreement.
	 
	 	6.6	 	Licensee agrees to include on both the outer packaging and on the package insert
of any Product an acknowledgement of the grant of rights by Licensor herein in the
following terms: “By license of Cosmo Technologies Ltd., Dublin, Ireland”.
	 
	 	6.7	 	The Parties shall establish a Development and Marketing Committee (“DMC”)
consisting of four (4) individuals (“Committee Members”), two (2) of whom shall be
nominated by

19

 

	 	 	 	Licensee and two (2) of whom shall be nominated by Licensor. Committee members may be
replaced by notice to the other Party and shall be appropriately qualified and
experienced in order to make a meaningful contribution to DMC meetings. The purpose of
the DMC is to provide a forum for the Parties to share information and knowledge on
the development and marketing of each Product, including, but not limited to, proposed
pre-marketing, marketing and promotional plans, reviewing competitor activity, and
discussing any regulatory, technical, quality assurance or safety issues in relation
to each Product. The DMC shall conduct its discussions in good faith with a view to
operating to the mutual benefit of the Parties and in furtherance of the successful
development and marketing of the Products in the Territory. The DMC shall meet as
often as the committee members may determine but in any event not less than two (2)
times per year. The DMC may invite individuals with special skills to attend such
meetings where considered to be relevant and appropriate.

	7	 	Development and Regulatory Matters.

	 	 	 	As for Product A:
	 
	 	7.1	 	Licensee acknowledges that Licensor has completed a phase II clinical trial for
the scope of Regulatory Approval for Product A both in the US and Europe for induction
of remission of mild to moderate Ulcerative Colitis. Licensee acknowledges that it has
been provided data on the outcome of such phase II clinical trials.
	 
	 	7.2	 	Licensee acknowledges that Licensor has currently phase III clinical trials
ongoing in Europe and US for the scope of Regulatory Approval for Product A in such
territories and that it has been provided with information on clinical trials design and
accepts such design.
	 
	 	7.3	 	Licensor shall be in charge of conducting such US phase III clinical trial for
induction of remission of mild to moderate Ulcerative Colitis including the conduct of
any extension trial, but Licensee shall have a right to supervise and manage all the
activities related to the US phase III clinical trial. Licensee acknowledges that
management of the phase III clinical trial in Europe and US could be optimized in the
interest of both Parties, through the supervision by the Steering Committee (SC) set
forth by Section 7.13. The SC shall be in charge of setting such

20

 

	 	 	 	optimization process with the objective to speed up Regulatory Approval. Independently
from this optimization, however, Licensor and Licensee undertake to provide each other
at no charge with all information that each one possesses or to which each one has
access that is related to the Product and is reasonably necessary to support Licensor
or Licensee’s application for Regulatory Approvals including: as for what pertains
Licensor (or its licensees in other territories), all information and data related to
the EU phase III clinical trial; as for what pertains Licensee, all information and
data related to the US phase III clinical trial; and agree that each Party shall have
a right of mutual reference at no-cost to the data the other Party shall gather for
the purpose of Product A Regulatory Approval.

	 	7.4	 	As soon as practically possible following completion of the ongoing phase III
clinical trial, Licensor shall transfer to Licensee all regulatory materials (and all
rights thereto, including the right to reference any drug master file) to allow Licensee
to file an NDA for the Territory. Notwithstanding the foregoing, Licensor shall
promptly share any development and/or regulatory data and information generated in
connection with Product A from time to time so as not to delay Licensee in filing and
obtaining necessary Regulatory Approvals.
	 
	 	7.5	 	Licensee shall be the primary Party responsible for regulatory matters in the
Territory. Licensee shall use commercially reasonable efforts to obtain and maintain all
Regulatory Approvals in the Territory. Licensee will ensure that such Regulatory
Approvals are kept in force at its own expense during the term of the Agreement, and
will notify Licensor of any material change in the status of Regulatory Approvals and
any extension thereof.
	 
	 	 	 	As for Product B
	 
	 	7.6	 	Licensee acknowledges that Licensor has completed a phase II clinical trial for
the scope of Product B Regulatory Approval both in the US and Europe for Traveller’s
Diarrhoea. Licensee acknowledges that it has been provided data on the outcome of such
phase II clinical trials.
	 
	 	7.7	 	Licensee acknowledges that, to complete development of Product B in order to file
for Product B Regulatory Approval for

21

 

	 	 	 	Traveller’s Diarrhoea in the Territory, a US phase III clinical trial shall be
required.

	 	7.8	 	Licensee shall be in charge of conducting the second of two pivotal phase III
clinical studies for Traveller’s Diarrhoea necessary to achieve Product B Regulatory
Approval. All costs pertaining to such phase III clinical study shall be borne by
Licensee. In this respect, Licensee acknowledges that Dr Falk Pharma GmbH (“Falk”) is
the Licensee of Product B and related patents for the EU territory plus Australia and
that, as such, it shall be in charge of conducting the first pivotal phase III clinical
study for Traveller’s Diarrhoea and whatever other clinical phase and/or studies may be
necessary to achieve Product B Regulatory Approval in its territory. Licensee
acknowledges that design and management of the phase III clinical trials for Traveler’s
Diarrhoea in Europe and US could be optimized in the interest of both Parties, through
the supervision by the Steering Committee (SC) set forth by Section 7.13 and mutual
access to trial data and mutual right of reference. Licensee shall initiate such second
pivotal phase III study promptly following receipt of necessary guidance from the FDA.
The SC shall be in charge of setting such optimization process, including assuming
decisions on strategic protocol design, with the objective to speed up Product
Regulatory Approval. Independently from this optimization, however, Licensor and
Licensee undertake to provide each other at no charge with all information that each one
possesses or to which each one has access that is related to the Product and is
reasonably necessary to support Licensor or Licensee’s application for Regulatory
Approval including: as for what pertains Licensor (or its licensees in other
territories), all information and data related to the EU phase III clinical trial; as
for what pertains Licensee, all information and data related to the US phase III
clinical trial; and agree that each Party shall have a right of mutual reference at
no-cost to the data the other Party shall gather for the purpose of Product B Regulatory
Approval.
	 
	 	7.9	 	As soon as practically possible following the pre-IND meeting with FDA, Licensor
shall transfer to Licensee all regulatory materials (and all rights thereto, including
the right to reference any drug master file) to allow Licensee to file the IND for the
Territory. Notwithstanding the foregoing, Licensor shall promptly share any development
and/or regulatory data and information generated in connection with Product B from time
to time so as

22

 

	 	 	 	not to delay Licensee in filing and obtaining necessary Regulatory Approvals.

	 	7.10	 	Licensee shall be the primary Party responsible for regulatory matters in the
Territory. Licensee shall therefore obtain and maintain all Regulatory Approvals in the
Territory. Licensee will ensure that such Regulatory Approvals are kept in force at its
own expense during the term of the Agreement, and will notify Licensor of any material
change in the status of the Regulatory Approvals and any extension thereof.
	 
	 	 	 	As for both Products
	 
	 	7.11	 	Each Party shall adhere to all requirements of Applicable Laws, rules and
regulations, including those which relate to reporting and investigation of adverse events
for the Products and shall be responsible for reporting all safety information, including
adverse events, to regulatory authorities in the Territory in compliance with such
requirements. For this purpose the Parties shall enter into pharmaco-vigilance agreement,
reasonably in advance of First Commercial Sale. The Parties shall report promptly to each
other any adverse event reports it receives related to the Products.
	 
	 	7.12	 	The Parties shall promptly notify each other in writing of the receipt or sending of
any correspondence from or to any Regulatory Authority in connection with safety or
quality issues concerning the Product. The Party with the most current filing with the
Regulatory Authority (an IND or filing for Regulatory Approval) for a Product shall be
responsible for responding to any correspondence or inquiry from any Regulatory Authority
in the Territory relating to such Product, provided that such Party shall keep the other
Party reasonably informed with respect to all such correspondence and inquiries, and its
responses thereto, and provided further that the other Party shall provide the responsible
Party with any reasonable assistance in responding to any such correspondence or inquiry.
Whenever there are FDA meetings, the Party receiving notice or initiating the meeting
shall provide appropriate notice to the other Party, in order to enable it to participate.
	 
	 	7.13	 	The Parties shall establish a Steering Committee (“SC”) consisting of four (4)
individuals (“Committee Members”), two (2) of whom shall be nominated by Licensee and two
(2) of whom shall be nominated by Licensor. Committee members may be replaced by

23

 

	 	 	 	notice to the other Party and shall be appropriately qualified and experienced in
order to make a meaningful contribution to Steering Committee meetings. The purpose of
the Steering Committee is to provide a forum for the Parties to share information and
knowledge on the development for the sake of most efficient Products Regulatory
Approval, including coordination with other licensees of the same Products. The
hosting Party shall prepare and distribute meeting minutes. If no unanimous decision
is taken, the issue shall be referred to both Licensor’s and Licensee’s CEOs. In case
of disagreement between CEOs, Licensee shall have the final say for the Territory.

	8	 	Intellectual Property.

	 	8.1	 	Licensor has registered the Trademark in the countries listed in Schedule C.
Licensee recognizes the exclusive legal ownership by Licensor of the Trademarks in the
Territory and Licensee agrees it will not at any time either during the term of this
Agreement or thereafter use the Trademarks in any manner that might infringe upon
Licensor’s ownership rights to the Trademarks directly or indirectly.
	 
	 	8.2	 	Licensee may use its own trademark(s) for making, using, and selling the Products
in the Territory in accordance with this Agreement. Licensor recognizes the exclusive
legal ownership by Licensee of such trademarks in the Territory and Licensor agrees it
will not at any time either during the term of this Agreement or thereafter use the
Licensee’s trademarks in any manner that might infringe upon Licensee’s ownership rights
to the such trademarks directly or indirectly. Nonetheless, Licensee shall use the
Trademark jointly with its own trademark(s) in all advertisements, promotions, press
releases and all kind of communications and the Products label, as submitted for
approval with FDA, shall be branded also with Licensor’s Trademark, unless otherwise
required by Applicable Laws.
	 
	 	8.3	 	Title to all inventions and other intellectual property related to the Products,
including any Improvements, made solely by Licensor or jointly by the Parties during the
term of this Agreement shall be owned by Licensor or jointly, as the case may be, and an
Exclusive license to such inventions and other intellectual property has been granted to
Licensee pursuant to sections 2.1 and 2.2 herein. Title to all inventions and other
intellectual property related to the Products, including any Improvements,

24

 

	 	 	 	made solely by Licensee during the term of this Agreement shall be owned by Licensee.

	 	8.4	 	Licensor represents and warrants that it is the rightful and sole owner of all of
the Patents, Know-How and the Trademarks free and clear of all security interests and
other encumbrances and it has full right to license same to Licensee.
	 
	 	8.5	 	Licensor represents and warrants that:

	 	8.5.1	 	It is unaware of any actual or threatened claim or action
brought alleging that the Patents, Know-How, Products or Trademarks, or their
use, violate any intellectual property rights of third parties or challenging
the validity, enforceability or scope of such Patents, Know-How or
Trademarks;
	 
	 	8.5.2	 	To the knowledge of Licensor or its Affiliates, the
marketing, use, distribution, or sale of Products in the Territory does not
and shall not infringe or otherwise conflict with any intellectual property
rights of third parties;
	 
	 	8.5.3	 	It is unaware of any third parties infringing on the
Patents, Know-How, or Trademark;
	 
	 	8.5.4	 	It will, at its own cost, use its best efforts to maintain
the Patents and prosecute any pending patent applications, to achieve patent
granting, provided that Licensee shall have the right to step-in to maintain
and prosecute the Patents in the Territory if Licensor fails to do so;
	 
	 	8.5.5	 	Products A and B are covered by the Patents, including at
least one issued Patent, and the Products, and their formulation and coating,
are as described in the materials provided to Licensee;
	 
	 	8.5.6	 	it holds, and is operating in compliance with, such
permits, licenses, authorizations and clearances of any Regulatory Authority
required in connection with the development to date of Products. Licensor
further represents and warrants to Licensee that it has not received any
warning letters or written correspondence from any Regulatory Authority or
other governmental entity requiring the termination, suspension or
modification of any clinical or pre-clinical studies or tests with respect to
Products;

25

 

	 	8.5.7	 	to the knowledge of Licensor, none of the Patents are
invalid or unenforceable.

	 	8.6	 	Except as stated in sections 8.4 and 8.5 of this Agreement, the license granted
herein with regard to the Products is provided “as is” and without warranty of
merchantability or warranty of fitness for a particular purpose. Therefore, in no event
shall Licensor be liable for any incidental, special or consequential damages resulting
from exercise of the license granted herein with regard to the Products; provided that
this limitation of liability shall not apply to such damages resulting from
manufacturing or handling of the products by Licensor or the other responsibilities of
the Licensor under this Agreement, the Supply Agreement or Applicable Laws.
	 
	 	8.7	 	Licensor hereby agrees to indemnify and hold Licensee, its successors and
assignees, harmless from and against any and all liabilities, demands, suits, losses,
claims of action, damages, costs and expenses which Licensee may incur, suffer or be
required to pay only by reason of violation of the representations and warranties set
above in 8.4 and 8.5.
	 
	 	8.8	 	Licensor shall have the primary right and responsibility, at its sole cost and
expense, to conduct and control prosecution and maintenance with respect to the Patents
and Trademarks, provided that Licensee shall reasonably co-operate and assist Licensor
in connection with such activities in the Territory. Licensor shall keep Licensee
reasonably informed as to the status of any of the Patents and Trademarks in the
Territory, and shall consider in good faith the reasonable requests and suggestions of
Licensee with respect to the prosecution and maintenance of the Patents and Trademarks
in the Territory. Licensor shall not abandon any of the Patents or Trademarks in the
Territory without providing reasonable prior written notice to Licensee of such
intention to surrender (which notice shall, in any event, be given no later than sixty
(60) days prior to the next deadline for any action that would result in such surrender
that may be taken with respect to such Patent or Trademark with the relevant patent and
trademark office) and providing Licensee an opportunity to assume responsibility for
such Patent or Trademark. In the event of surrender, if Licensee elects to assume
responsibility for any Patent or Trademark, Licensor shall, at Licensee’s expense,
assign all right, title and interest in such Patent or Trademark to Licensee, and
Licensor shall promptly take all actions reasonably

26

 

	 	 	 	necessary or desirable to perfect such interest in Licensee; provided that Licensor
will retain all rights and obligations with respect to such Patent or Trademark before
the date of such assignment.

	 	8.9	 	Each Party shall notify the other if it becomes aware of any infringement or
potential infringement of the Patents or the infringement or potential infringement of
third party patent rights by exercise of the making, use, or sale of the Products,
whether in the Territory or elsewhere. If a Party learns of any such infringement, such
Party shall so inform the other Party and provide it with reasonable evidence of such
infringement.
	 
	 	8.10	 	Each Party shall notify and provide the other Party with copies of any allegations of
alleged patent invalidity, unenforceability or non-infringement of any Patent pursuant to
a Paragraph IV Patent Certification by a third party filing an Abbreviated New Drug
Application, an application under §505(b)(2), or other similar patent certification by a
third party (“Paragraph IV Claim”). Such notification and copies shall be provided as
soon as practicable, and at least within five (5) working days after the Party receives
such certification, and shall be sent by facsimile and overnight courier to the other
Party.
	 
	 	8.11	 	Licensee shall have the right to notify a third party of the infringement of Patent
or Trademark rights or enforce the Patents or Trademarks against a third party without the
consent of Licensor if the infringement has occurred within the Territory or pursuant to a
Paragraph IV Claim. Both Parties shall use reasonable efforts and cooperation to terminate
infringement without litigation. However, in the event of litigation, Licensee shall have
sole right to institute, prosecute, and control such litigation at its own expense.
Licensor shall cooperate fully in such litigation, and in the case where Licensee desires
to bring such litigation, at Licensee’s request, Licensor agrees to join any such
litigation and proceed as sole plaintiff if necessary to enforce such Patent(s) against
the third party(ies), at Licensee’s own expense. Licensor shall have the right to approve
any settlement that would adversely affect the Patents or Licensor’s rights under this
Agreement or result in any liability or admission on behalf of Licensor, such approval not
to be unreasonably withheld, conditioned, or delayed. Licensor may appoint its own
attorneys at its own expense. In the event Licensee does not elect to

27

 

	 	 	 	institute, prosecute or control such litigation, Licensor shall have the right to do
so at its own expense.

	 	8.12	 	If a third party commences legal action against Licensee claiming the exercise of the
license rights by Licensee granted hereunder infringes a third party’s intellectual
property rights, Licensee shall defend such litigation at its own expense (subject to
Licensor’s indemnification obligation, if any). Licensor shall cooperate fully in such
litigation and, at Licensee’s request, Licensor agrees to join any such litigation at
Licensee’s own expense.
	 
	 	8.13	 	All monetary recoveries from any action brought by a Party pursuant to Sections 8.9
 — 8.12 shall belong to the Party bringing suit, after reimbursement of reasonable legal
expenses pursuant to said Sections.
	 
	 	8.14	 	Licensee shall mark all packaging of Products under the terms of this Agreement, or
their containers, with the licensed Trademark in accordance with the Applicable Laws.
	 
	 	8.15	 	The Parties acknowledge that Licensee, as designated holder of any NDA pursuant to
this Agreement for all Products, may refer to applicable Patents in the listings for
Products in the Orange Book. At Licensee’s request, Licensor and its Affiliates shall
support Licensee in listing the applicable Patents, such support not to be unreasonably
withheld, conditioned, or delayed. In the event that any Patent is listed in the Orange
Book, Licensee shall use commercially reasonable efforts to ensure that Licensor shall be
listed as the assignee of such Patent and Licensee or its Affiliate shall be identified as
the point of contact for any Paragraph IV Claims. Licensor and Licensee shall co-operate
with respect to data exclusivity periods (such as those periods listed in the FDA’s Orange
Book including any available paediatric extensions) at Licensee’s expense.

	9	 	Confidentiality.

	 	 	 	Each Party agrees to maintain in confidence and not to use except for the purpose of
    this Agreement any information of a confidential nature such as technical
information and data, commercial information and know-how, price structures,
administrative and operational costs, or other information relating to each other’s
business operations or in the case of Licensee to the Products, whether disclosed
prior to the Effective Date or thereafter. Each Party’s obligation of

28

 

	 	 	 	confidence and limitation upon use shall not apply to any information to the extent
that the receiving Party can show that such information:

	 	(a)	 	is or became generally available to the public otherwise than
by reason of breach by the receiving Party of the provisions of this Agreement;
	 
	 	(b)	 	was known to the receiving Party prior to the date of the
Agreement provided that documentary evidence of such knowledge is provided to
the disclosing Party on request;
	 
	 	(c)	 	was subsequently disclosed to the receiving Party without
obligation of confidence by a third party owing no such obligations to the
disclosing Party in respect of such information;
	 
	 	(d)	 	is required by law to be disclosed but then only when, to the
extent reasonably practicable, prompt notice of this requirement has been given
to the original disclosing Party so that it may seek appropriate relief to
prevent or limit such disclosure.

	 	 	 	Except as required by Applicable Laws or court order or as otherwise permitted under
this Agreement, all publicity, press releases and public announcements, in each case
relating to Products in the Territory and/or the transactions contemplated hereby
shall be reviewed in advance by, and shall be subject to the written approval (such
approval not to be unreasonably withheld) of both Parties. Either Party may disclose
the existence of this Agreement and the terms and conditions hereof, without the prior
written consent of the other Party, as may be required by Applicable Laws (including
the disclosure requirements of any stock exchange in the Territory), in which case the
Party seeking to disclose the information shall give the other Party reasonable
advance notice and review of any such disclosure and shall seek confidential treatment
of such information to the extent possible under Applicable Law.
	 
	 	 	 	Parties also agree that, whenever possible, they will try to coordinate in advance
diffusion of information on Products with other licensees of Products in other
territories.
	 
	 	 	 	This clause shall remain in force for five years following the expiry or termination
of this Agreement.

	10	 	Termination

29

 

	 	10.1	 	Subject to the provisions contained herein which provide for earlier termination,
this Agreement shall commence on the Effective Date and shall remain in effect for 50
(fifty) years following the Royalty Term.
	 
	 	10.2	 	Following the Royalty Term with respect to each Product, the Parties shall
negotiate in good faith towards establishing a reduced royalty arrangement under the
Know-How and Trademarks license. If the Parties are unable to reach an agreement, they
shall engage an appropriate third party expert to establish the reduced royalty rate
arrangement.
	 
	 	10.3	 	If either Licensor or Licensee breaches any of the terms and conditions of this
Agreement, the other Party may give notice of the breach to the Party in default. If
the defaulting Party does not rectify the breach within 60 (sixty) days after receipt of
the notice, the Party who gave notice may terminate this Agreement upon the expiration
of the 60 (sixty) day period without prejudice to such Party’s claims for damages or
indemnification for the losses incurred by reason of such termination or breach of the
Agreement.
	 
	 	10.4	 	Licensee may withdraw from this Agreement without penalty or further obligation to
Licensor on a Product by Product basis upon 60 (sixty) days written notice to Licensor if
such Product (i) fails to achieve the primary end points in the applicable phase III
clinical trial to support Regulatory Approval with statistical significance, or (ii) the
clinical trials conducted with respect to such Product are not sufficient to enable
Licensee to obtain all necessary Regulatory Approvals for such Product, in each case
within 5 (five) years after the Effective Date. Payments made by Licensee to Licensor
until the moment such notice of withdrawal is sent shall not be reimbursed.
	 
	 	10.5	 	Upon termination of this Agreement, Licensee may dispose of all Products on hand
within a period of one hundred and twenty (120) days of the effective date of such
termination provided that the sale of such Products by Licensee or Affiliates shall be
subject to the terms of this Agreement, including but not limited to the rendering of
reports and payment of royalties required under this Agreement.
	 
	 	10.6	 	In the event Licensor terminates this Agreement according to section 10.3 or
Licensee withdraws according to section 10.4, then

30

 

	 	 	 	Licensee shall transfer or assign all Regulatory Approvals to Licensor.

	11	 	Miscellaneous

	 	11.1	 	Each Party represents and warrants to the other that:

	 	11.1.1	 	It is a company duly organized, validly existing and in good standing
under the laws of the jurisdiction of its formation;
	 
	 	11.1.2	 	it has the power and authority to enter into and be bound by the terms of
this Agreement and to perform its obligations hereunder;
	 
	 	11.1.3	 	it has taken all necessary action on its part to authorize the execution
and delivery of this Agreement and this Agreement has been duly executed and
delivered on its behalf and constitutes a legal, valid and binding
obligation enforceable against it in accordance with its terms; and
	 
	 	11.1.4	 	it is subject to no legal, contractual or other restrictions, limitations
or conditions which conflict with its rights and obligations under this
Agreement or which might affect adversely its ability to perform hereunder.

	 	11.2	 	Neither Party to this Agreement shall be liable for failure to perform if the
failure is attributable to any cause which is reasonably beyond the Party’s control,
including:

	 	11.2.1	 	war (declared or undeclared), riot, political insurrection, rebellion,
revolution, act of terrorism;
	 
	 	11.2.2	 	acts or orders of or expropriation by any government (whether de facto or de
jure) prohibiting the import or export of the goods covered hereby or imposing
rationing;
	 
	 	11.2.3	 	strike, lockout, or other labor troubles which interfere with the manufacture,
sale or transportation of the goods covered hereby or with the supply of raw
materials necessary for their production;
	 
	 	11.2.4	 	fire, flood, explosion, earthquake, tornadoes, disease outbreaks or other
natural events.

31

 

	 	11.3	 	Each Party will indemnify and hold the other Party and their Affiliates harmless
from and against any and all claims, judgements, costs, awards, expenses (including
reasonable attorneys’ fees) and liabilities of every kind arising out of any breach by
such Party of its warranties and covenants or other obligations contained herein;
provided that, with respect to product liability, Licensor will be liable for claims
arising from its fault or negligence in manufacturing the Products and Licensee will be
liable for claims arising from its fault or negligence in selling and distributing the
Products.
	 
	 	11.4	 	Each Party shall be solely responsible for its accounting and tax reporting
obligations related to this Agreement and shall indemnify and hold the other Party and
their Affiliates harmless from and against any and all claims, judgements, costs,
awards, expenses (including reasonable attorneys’ fees) and liabilities of every kind
arising out of the accounting or tax activities of the indemnifying Party.
	 
	 	11.5	 	Nothing in this Agreement or in the activities engaged in by the Parties hereunder
shall create an agency, partnership, employment or joint venture relationship between the
Parties.
	 
	 	11.6	 	Any notice authorized or required to be given under the terms of this Agreement shall
be given by facsimile transmission or international courier sent to:

If to Licensor:

Cosmo Technologies Limited

4243 Amiens Street

Dublin 1

Ireland

Fax n. +353 1 8230718

To the attention of Office Manager

With copy to:

Cosmo Pharmaceuticals S.p.A.

Via Cristoforo Colombo 1,

20020 LAINATE (Mi)

Italy

Fax n. +39 02 93337663

32

 

To the attention of Mr. Giuseppe Cipriano

To Licensee

Santarus, Inc.

3721 Valley Centre Drive, Suite 400

San Diego, California 92130

Attention: Legal Affairs Department

Fax: + 01 (858) 314-5702

	 	 	 	(or such other address as the addressee may previously by notice to the other Party
have stipulated). Notices shall be deemed to be given in the case of a facsimile
transmission when sent provided it is confirmed by international courier sent not
later than the next business day and in the case of international courier upon the
receipt by the other Party.
	 
	 	11.7	 	In the event one or more terms of this Agreement are found to violate the provisions
of any applicable statute, law or regulation, the Parties hereto shall negotiate in good
faith to modify this Agreement, but only to the extent necessary to make the terms of this
Agreement valid and enforceable, having full regard for all applicable laws and the intent
and purposes of the Parties entering into this Agreement.
	 
	 	11.8	 	Neither this Agreement nor any interest hereunder shall be assignable or otherwise
transferable by operation of law by either Party without the prior written consent of the
other Party hereto. No consent shall be required and an assignment shall be permitted to
an Affiliate or an acquirer of all or substantially all of the assigning Party’s assets to
which this Agreement relates, or upon a merger, change of control or to a successor in
business which agrees to be bound by all terms and conditions of this Agreement. Any
attempted assignment in contravention of this Section 11.8 shall be void and without any
force or effect. This Agreement shall be binding upon and inure to the benefit of and be
enforceable by the Parties hereto and their respective successors and assigns.
	 
	 	11.9	 	The failure of either Party in any one or more instances to insist upon strict
performance of any of the terms and conditions of this Agreement shall not be construed as
a waiver or relinquishment, to any extent, of the right to assert or rely upon any such
terms or conditions on any future occasion.

33

 

	 	11.10	 	This Agreement and its Schedules constitutes the definitive agreement of the Parties
on the subject matter hereof and supersedes, cancels and annuls all prior agreements,
understandings and undertakings relating to the subject matter hereof. This Agreement
shall not be modified or amended except by a written document signed by a duly authorized
officer of the Parties. There are no verbal agreements, warranties, representations or
understandings affecting this Agreement and all previous or other negotiations,
representations, and understandings between the Parties are merged herein.
	 
	 	11.11	 	This Agreement shall be governed by and construed in accordance with the laws of
Italy without regard to the conflicts of laws provisions thereof and without regard to the
United Nations Convention on Contracts for the Sale of Goods. In the event of any dispute
arising out of or in connection with the present Agreement, the Parties agree that such
dispute shall be finally settled under the Rules of Arbitration of the International
Chamber of Commerce — ICC by a panel of three arbitrators appointed in accordance with
the said Rules of Arbitration. The arbitrators shall apply Italian Law. The seat of
arbitration shall be Paris (France) and the language of the arbitration proceeding shall
be English.
	 
	 	11.12	 	The following documents constitute Schedules to this Agreement: A) list of Patents
for Product A; B) list of Patents for Product B; C) list of Trademarks; D) Stock Issuance
Agreement; E) Rights Registration Agreement; F) Products Specifications.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly
authorized representatives, as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Cosmo Technologies Limited	 	 	 	Santarus, Inc.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Signature:	 	/s/ Giuseppe Cipriano	 	 	 	Signature:	 	/s/ Gerald T. Proehl	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Giuseppe Cipriano
	 	 	 	 	 	Name:
	 	Gerald T. Proehl	 	 
	 

	 	Title:
	 	CEO
	 	 	 	 	 	Title:
	 	President and CEO	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Date: December 10, 2008	 	 	 	Date: December 10, 2008	 	 

34exv10w26

Exhibit 10.26

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

STOCK ISSUANCE AGREEMENT

     This STOCK ISSUANCE AGREEMENT (the “Agreement”) is made as of the tenth day of December, 2008
(the “Effective Date”), by and between Santarus, Inc., a Delaware corporation (the “Company”), and
Cosmo Technologies Limited, an Irish corporation (“Investor”). Any capitalized terms not defined
in this Agreement shall have the meanings given to them in that certain License Agreement between
the Company and Investor dated as of the Effective Date (the “License Agreement”).

     THE PARTIES HEREBY AGREE AS FOLLOWS:

     1. Issuance of Shares.

          1.1 Issuance of Shares. Subject to the terms and conditions of this Agreement, in
consideration of the execution and delivery of that certain License Agreement, the Company agrees
to issue to Investor:

               (a) at the Initial Closing, six million (6,000,000) shares (the “Initial Shares”) of the
Company’s Common Stock, par value $0.0001 per share (“Common Stock”); and

               (b) subject to the conditions and limitations set forth in Section 1.2 below, at each
Milestone Closing, the number of shares of Common Stock (in each case, the “Milestone Shares”)
equal to the Milestone Payment (as defined below) then due divided by one hundred percent (100%) of
the average daily closing price of the Common Stock reported by the Nasdaq Global Market for the
thirty (30) consecutive trading days ending on the day immediately prior to the achievement of the
applicable Milestone Event rounded to the lower full share amount with the fraction paid in cash.
The Initial Shares and the Milestone Shares are collectively referred to herein as the “Shares.”

 

 

          1.2 Milestone Shares. At the election of Investor (such election to be made within
thirty (30) days from the receipt by Investor of notice that a Milestone Event has occurred), each
Regulatory Milestone and Commercial Milestone shall be paid in shares of Common Stock.
Notwithstanding the foregoing, the Company shall not be obliged to issue Milestone Shares to
Investor at the occurrence of a Milestone Event if either:

          (a) the aggregate number of Shares issued to Investor (including the Initial Shares), as a
result of cumulative election by Investor, shall exceed 10.300.000 shares; or

          (b) such issuance could reduce the amount of the Company’s accumulated net operating losses
deductible for tax purposes against future earnings (Internal Revenue Code Section 382) in excess
of USD [***]
([***] dollars), as determined by the Company.

     If the Company is not obligated to issue Milestone Shares to Investor at the occurrence of a
Milestone Event as a result of (a) or (b) above, the Company shall pay such Milestone in cash by
means of wire transfer on the account designated by Investor within ten (10) working days after
receipt by the Company of notice of Investor’s election.

          1.3 Closings.

               (a) The initial closing for the issuance of the Initial Shares shall take place at the offices
of Latham & Watkins LLP, 12636 High Bluff Drive, Suite 400, San Diego, California, three (3)
working days following the Effective Date, or at such other time and place as the Company and
Investor mutually agree upon orally or in writing (which time and place are designated as the
“Initial Closing”).

               (b) The closings for the issuance of any Milestone Shares shall take place at the offices of
Latham & Watkins LLP, 12636 High Bluff Drive, Suite 400, San Diego, California, ten (10) working
days following receipt by the Company from the Investor of its election to receive the Milestone
Payment in the form of the Milestone Shares, or at such other time and place as the Company and
Investor mutually agree upon orally or in writing (which time and place are

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

designated as a “Milestone Closing” and together with the Initial Closing, a “Closing”).

               (c) At each Closing, the Company shall deliver to Investor a certificate representing the
Initial Shares or the Milestone Shares, as the case may be. No cash consideration is payable by
the Investor in connection with the issuance of any Shares.

          1.4 Registration Rights Agreement. In connection with the issuance of the Shares, the
Company and Investor have entered into a Registration Rights Agreement dated as of the Effective
Date, providing for the registration for resale of the Initial Shares and, when and if issued, the
Milestone Shares (the “Registration Rights Agreement”).

     2. Representations and Warranties of the Company. The Company hereby represents and
warrants to Investor that:

          2.1 Organization, Good Standing and Qualification. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware and has
all requisite corporate power and authority to carry on its business as now conducted and as
proposed to be conducted. The Company is duly qualified to transact business and is in good
standing in each jurisdiction in which the failure so to qualify as the case may be, would not
reasonably be expected, individually or in the aggregate, to (i) materially and adversely affect
the legality, validity or enforceability of this Agreement, (ii) have or result in a material
adverse effect on the results of operations, assets, business or financial condition of the
Company, or (iii) materially and adversely impair the Company’s ability to perform fully on a
timely basis its obligations under this Agreement (any of (i), (ii) or (iii), a ”Material
Adverse Effect”). The Company has no subsidiaries. The Company is not in violation of any of the
provisions of its certificate of incorporation or bylaws.

          2.2 Authorization. The Company has all requisite corporate power and authority (i) to
execute, deliver and perform its obligations under this Agreement; (ii) to issue the Shares in the
manner and for the purpose contemplated by this Agreement, and (iii) to execute, deliver and
perform its obligations under all other agreements and instruments executed and delivered by it
pursuant to or in connection with this Agreement. All corporate action on the part of the Company,
its officers, directors and stockholders necessary for the authorization, execution and delivery of
this Agreement, the performance of all obligations of the Company

 

 

hereunder and the authorization, issuance (or reservation for issuance) and delivery of the
Shares has been taken or will be taken prior to the Closing, and this Agreement constitutes a valid
and legally binding obligation of the Company, enforceable in accordance with its terms, except (i)
as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of
general application affecting enforcement of creditors’ rights generally and (ii) as limited by
laws relating to the availability of specific performance, injunctive relief or other equitable
remedies.

          2.3 Valid Issuance of Securities. The Shares which are being issued hereunder, when
issued, sold and delivered in accordance with the terms hereof for the consideration expressed
herein, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens,
charges, claims, security interests or encumbrances (except as set forth herein) and shall not be
subject to preemptive or similar rights of stockholders, and, based in part upon the
representations of Investor in this Agreement, the Shares will be issued in compliance with all
applicable federal and state securities laws.

          2.4. No Conflicts. The execution, delivery and performance of this Agreement and the
consummation by the Company of the transactions contemplated hereby do not, and will not, (i)
conflict with or violate any provision of the Company’s certificate of incorporation or bylaws,
(ii) conflict with, or constitute a default under any material agreement to which the Company is a
party or by which any material property or asset of the Company is bound, except to the extent that
such conflict, violation or default (A) could not reasonably be expected to have a Material Adverse
Effect or (B) is waived pre-Closing, or (iii) result in a violation of any law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company is subject, or by which any material property or asset of the Company is bound,
except to the extent that such violation could not reasonably be expected to have a Material
Adverse Effect. The Company has reserved from its duly authorized capital stock the maximum number
of Shares.

          2.5 Capitalization. The capitalization of the Company as of September 30, 2008, is as
set forth in the most recent applicable SEC Report (as defined below), increased as set forth in
the next sentence. The Company has not issued any capital stock since that date other than
pursuant to (i) employee and director benefit option or stock purchase plans disclosed in the SEC
Reports, or (ii) outstanding warrants, options or other securities disclosed in the SEC Reports.
The outstanding shares of capital stock of the Company have been duly and validly

 

 

issued and are fully paid and nonassessable and have been issued in compliance with all
federal and state securities laws.

          2.6 Absence of Litigation. Except as disclosed in the Company’s SEC Reports, there is
no action, suit, claim, or proceeding, or, to the Company’s knowledge, inquiry or investigation,
before or by any court, public board, government agency, self-regulatory organization or body
pending or, to the knowledge of the Company, threatened against or affecting the Company that could
have a Material Adverse Effect.

          2.7 SEC Reports; Financial Statements. The Company has filed all reports required to
be filed by it under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
including pursuant to Section 13(a) or 15(d) thereof, for the twelve months preceding the date
hereof (the foregoing materials (together with any materials filed by the Company under the
Exchange Act and the Securities Act of 1933, as amended (the “Securities Act”), whether or not
required) being collectively referred to herein as the “SEC Reports”) on a timely basis or has
received a valid extension of such time of filing and has filed any such SEC Reports prior to the
expiration of any such extension. As of their respective dates, the SEC Reports complied in all
material respects with the requirements of the Securities Act and the Exchange Act and the rules
and regulations of the Securities and Exchange Commission (the “SEC”) promulgated thereunder, and
none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted
to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.

          2.8 No General Solicitation; Placement Agent’s Fees. Neither the Company, nor, to the
Company’s knowledge, any of its Affiliates, nor any person acting on its or, to the Company’s
knowledge, on their behalf, has engaged in any form of general solicitation or general advertising
(within the meaning of Regulation D) in connection with the offer or sale of the Shares. The
Company shall be responsible for the payment of any placement agent’s fees, financial advisory
fees, or brokers’ commissions relating to or arising out of the issuance of the Shares pursuant to
this Agreement. The Company shall pay, and hold Investor harmless against, any liability, loss or
expense (including, without limitation, reasonable attorney’s fees and out-of-pocket expenses)
arising in connection with any such claim for fees (other than for persons engaged by, or on behalf
of, Investor or its agents or investment advisors) arising out of the issuance of the Shares
pursuant to this Agreement.

 

 

          2.9 Private Placement. Neither the Company nor any person acting on the Company’s
behalf has, directly or indirectly, at any time within the past six months, made any offer or sale
of any security or solicitation of any offer to buy any security under circumstances that would (i)
eliminate the availability of the exemption from registration under Regulation D under the
Securities Act in connection with the offer and issuance by the Company of the Shares as
contemplated hereby or (ii) cause the offering of the Shares pursuant to this Agreement to be
integrated with prior offerings by the Company for purposes of any applicable law, regulation or
stockholder approval provisions, including, without limitation, under the rules and regulations of
any Trading Market (as defined in the Registration Rights Agreement).

          2.10 Form S-3 Eligibility. The Company is eligible to register the Shares for resale
by the Investor using Form S-3 promulgated under the Securities Act.

          2.11 Listing and Maintenance Requirements. The Company has not, in the twelve months
preceding the date hereof, received written notice from any Trading Market on which its Common
Stock is or has been listed or quoted to the effect that the Company is not in compliance with the
listing or maintenance requirements of such Trading Market. The Company is in compliance with all
such material listing and maintenance requirements.

          2.12 Registration Rights. Except as disclosed in or contemplated by the SEC Reports,
the Company has not granted or agreed to grant to any person any rights (including “piggy-back”
registration rights) to have any securities of the Company registered with the SEC or any other
governmental authority. The Investor acknowledges that certain stockholders of the Company may be
entitled to exercise piggy-back registration rights in connection with the registration of the
resale of the Shares.

     3. Representations and Warranties of the Investor. Investor hereby represents and
warrants that:

          3.1 Organization, Good Standing and Qualification. Investor is a corporation duly
organized, validly existing and in good standing under the laws of Ireland and has all requisite
corporate power and authority to carry on its business as now conducted and as proposed to be
conducted.

          3.2 Authorization. All corporate action on the part of Investor, its

 

 

officers and directors necessary for the authorization, execution and delivery of this
Agreement, the performance of all obligations of Investor hereunder has been taken or will be taken
prior to the Closing, and this Agreement constitutes a valid and legally binding obligation of
Investor enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting the
enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies.

          3.3 Shares Received Entirely for Own Account. The Shares to be received by Investor
will be acquired for investment for Investor’s own account, not as a nominee or agent, and not with
a view to the resale or distribution of any part thereof, and Investor has no present intention of
selling, granting any participation in, or otherwise distributing the same. By executing this
Agreement, Investor further represents that Investor does not have any contract, undertaking,
agreement or arrangement with any person to sell, transfer or grant participations to such person
or to any third person, with respect to any of the Shares. Investor represents that it has full
power and authority to enter into this Agreement.

          3.4 Investment Experience. Investor acknowledges that it is able to fend for itself,
can bear the economic risk of its investment and has such knowledge and experience in financial or
business matters that it is capable of evaluating the merits and risks of the investment in the
Shares. Investor also represents it has not been organized for the purpose of acquiring the
Shares.

          3.5 Accredited Investor. Investor is an “accredited investor” within the meaning of
SEC Rule 501 of Regulation D, as presently in effect.

          3.6 Restricted Securities. Investor understands that the Shares it is purchasing are
characterized as “restricted securities” under the federal securities laws inasmuch as they are
being acquired from the Company in a transaction not involving a public offering and that under
such laws and applicable regulations such Shares may be resold without registration under the
Securities Act, only in certain limited circumstances. In this connection, Investor represents
that it is familiar with SEC Rule 144, as presently in effect, and understands the resale
limitations imposed thereby and by the Securities Act.

          3.7 Further Limitations on Disposition. Without in any way limiting the
representations set forth above or the obligations set forth in Section 4.1, Investor further
agrees not to make any disposition of all or any portion of the

 

 

Shares unless and until the transferee has agreed in writing for the benefit of the Company to
be bound by Sections 3.7, 4.2, 4.3 and 5 of this Agreement, if applicable, and:

               (a) There is then in effect a Registration Statement under the Securities Act covering such
proposed disposition and such disposition is made in accordance with such Registration Statement;
or

               (b) (i) Investor shall have notified the Company of the proposed disposition and shall have
furnished the Company with a reasonably detailed statement of the circumstances surrounding the
proposed disposition, and (ii) if reasonably requested by the Company, such Investor shall have
furnished the Company with an opinion of counsel (which may be Investor’s inside counsel), in form
and substance reasonably satisfactory to the Company, that such disposition will not require
registration of such shares under the Securities Act. It is agreed that the Company will not
require opinions of counsel for transactions made pursuant to Rule 144 except in unusual
circumstances.

          3.8 Legends. It is understood that the certificates evidencing the Shares may bear
one or all of the following legends:

               (a) “These securities have not been registered under the Securities Act of 1933, as amended.
They may not be sold, offered for sale, pledged or hypothecated in the absence of a registration
statement in effect with respect to the securities under such Act or an opinion of counsel
satisfactory to the Company that such registration is not required or unless sold pursuant to Rule
144 of such Act.”

               (b) “These securities are subject to certain transfer restrictions contained in a certain
Stock Issuance Agreement dated December 10, 2008, as amended from time to time, a copy of which may
be obtained from the corporation without charge.”

               (c) Any legend required by any applicable state securities laws.

     To the extent that such legends are no longer applicable, the Company shall cause its transfer
agent to remove the legends upon request by Investor.

     4. Covenants of Investor.

 

 

               4.1 Transfer Restriction. Investor hereby agrees that during the time period
commencing as of the Initial Closing until fifteen (15) months following the Initial Closing (with
such time period being referred to as the “Initial Restricted Period”), that neither it nor any
Affiliate shall, directly or indirectly sell, offer to sell, contract to sell (including, without
limitation, any short sale), grant any option to purchase or otherwise transfer or dispose of
(other than to donees who agree to be similarly bound) any of the Shares at any time during the
Initial Restricted Period. Investor hereby also agrees that during the time period commencing as
of the date on which the Company provides notice to the Investor that a Milestone Event has occured
(the “Milestone Share Issuance Date”) until six (6) months following that date (with each such time
period being referred to as a “Milestone Restricted Period” for the applicable Milestone Shares
issued within such period only), that neither it nor any Affiliate shall, directly or indirectly
sell, offer to sell, contract to sell (including, without limitation, any short sale), grant any
option to purchase or otherwise transfer or dispose of (other than to donees who agree to be
similarly bound) any of the Milestone Shares during the applicable Milestone Restricted Period. In
order to enforce the foregoing covenant, the Company may impose legends with respect to the Shares
held by Investor (and the Shares of every other person subject to the foregoing restriction) until
six (6) months following the Initial Closing or the applicable Milestone Share Issuance Date;
provided that the Company may impose stop transfer instructions and Investor shall continue to be
subject to the transfer restrictions set forth herein through the entire Initial Restricted Period
or applicable Milestone Restricted Period. Following the last day of the last Milestone Restricted
Period, any restrictions under this Section 4.1 shall terminate and be of no further force and
effect.4,2 Standstill Provisions. Subject to the following, for a period of two (2) years
commencing as of the Initial Closing, Investor (including all Affiliates) shall not acquire
beneficial ownership of any shares of Common Stock of the Company, any securities convertible into
or exchangeable for Common Stock, or any other right to acquire Common Stock, except by way of
stock dividends or other distributions or offerings made available to holders of Common Stock
generally (collectively, “Company Stock”), from the Company or any other person or entity, without
the prior written consent of the Company, which consent may be withheld in its sole discretion;
provided, however, that (i) in no event shall the issuance of Shares pursuant to this Agreement
constitute a violation of this Section 4.2; (ii) in the event that following the expiration of the
applicable periods set forth in Section 4.1 Investor sells a portion of the Shares, Investor may
purchase up to the same number of Shares it has sold (provided that Investor provides notice to the
Company within three (3) working days following any such purchase); and (iii) the

 

 

provisions of this Section 4.2 shall be inoperative and of no force or effect if a Competing
Transaction occurs with respect to the Company. “Competing Transaction” shall mean that a person
(as defined by Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (“Person”)),
other than Cosmo or its affiliates and other than the Company or its subsidiaries: (A) enters into
an agreement providing for the merger or consolidation, or any similar transaction, involving the
Company in which, following consummation of such transaction, substantially all of the persons or
entities who, immediately prior to such transaction, had beneficial ownership of 50% or more of the
voting power of the Company do not continue to beneficially own at least 50% of the voting power of
the combined entity and do not have the ability to elect a majority of the directors of the
combined entity, (B) enters into an agreement providing for the purchase or other acquisition of,
or purchases or otherwise acquires, more than 40% of the assets of the Company, (C) enters into an
agreement providing for the purchase or other acquisition of, or purchases or otherwise acquires,
beneficial ownership of securities representing 40% or more of the voting power of the Company, (D)
commences a tender offer or exchange offer with respect to securities representing 40% or more of
the voting power of the Company, or (E) enters into an agreement or commences a proxy solicitation
in which the Person would acquire the ability to elect a majority of the Board of Directors of the
Company.

          4.3 Market Stand-off. The Investor hereby agrees that during the period of duration
not to exceed 180 days specified by the Company and an underwriter of capital stock of the Company,
following the effective date of a registration statement pursuant to which the Company is offering
securities under the Securities Act, it shall not, to the extent requested by the Company and such
underwriter (and provided the same restriction is agreed to by the officers and directors of the
Company), directly or indirectly sell, offer to sell, contract to sell (including, without
limitation, any short sale but excluding private placements in reliance on the so-called “4(1-1/2)”
exemption under the Securities Act), grant any option to purchase or otherwise transfer or dispose
of (other than to donees who agree to be similarly bound) any securities of the Company held by it
at any time during such period except Common Stock included in such registration. In order to
enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to
the Shares until the end of such period.

          4.4 Breach of License Agreement. In the event that Investor notifies the Company of
the occurrence of a material breach by the Company in accordance with the terms of the License
Agreement which breach is not rectified

 

 

in the opinion of Investor in accordance with the terms of the License Agreement, then the
restrictions set forth in Section 4.1 shall terminate and be of no further force and effect. The
Company agrees to remove any existing stop transfer instruction if such breach is not rectified in
the opinion of Investor.The Company would reserve the right to challenge such determination of a
breach under the License Agreement..

     5. Additional Notification. Investor agrees to provide the Company with oral or
written notice at least three (3) working days before buying shares of Common Stock, selling,
offering to sell, contracting to sell (including, without limitation, any short sale), granting any
option to purchase or otherwise transferring or disposing of any of the Shares and shall provide
the Company with the reasonable opportunity to bid on any such Shares.

     6. Company Covenants.

          6.1 Reports Under Exchange Act. With a view to making available to the Investor the
benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit the
Investor to sell the Shares to the public without registration, the Company agrees to: (a) make
and keep public information available, as those terms are understood and defined in Rule 144, at
all times; (b) file with the SEC in a timely manner all reports and other documents required of
the Company under the Securities Act and the Exchange Act; and (c) furnish to the Investor, so
long as the Investor owns any Shares, forthwith upon request (i) a written statement by the Company
that it has complied with the reporting requirements of Rule 144, the Securities Act and the
Exchange Act, (ii) a copy of the most recent annual or quarterly report of the Company and such
other reports and documents so filed by the Company, and (iii) such other information as may be
reasonably requested in availing the Investor of any rule or regulation of the SEC which permits
the selling of any Shares without registration.

          6.2 Rights Plans. The Company will amend its Rights Agreement dated as of November
12, 2004, as amended April 19, 2006, in the form previously provided to the Investor.

 

 

     7. Miscellaneous.

          7.1 Survival of Warranties. The warranties, representations and covenants of the
Company and Investor contained in or made pursuant to this Agreement shall survive the execution
and delivery of this Agreement and the Closing and shall in no way be affected by any investigation
of the subject matter thereof made by or on behalf of the Investor or the Company.

          7.2 Successors and Assigns. Except as otherwise provided herein, the terms and
conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties (including transferees of any of the Shares sold hereunder).
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

          7.3 Governing Law. This Agreement shall be governed by and construed under the laws
of the State of Delaware as applied to agreements among Delaware residents entered into and to be
performed entirely within Delaware.

          7.4 Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

          7.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used
for convenience only and are not to be considered in construing or interpreting this Agreement.

          7.6 Notices. Any notice authorized or required to be given under the terms of this
Agreement shall be given by facsimile transmission or international courier sent to:

If to the Company:

Santarus, Inc.

3721 Valley Centre Drive, Suite 400

San Diego, California 92130

Attn: Legal Affairs Department

Fax: +01 (858) 314-5702

 

 

If to Investor:

Cosmo Technologies Limited

4243 Amiens Street

Dublin 1

Ireland

Attention: Office Manager

Fax: +353 1 8230718

               (or such other address as the addressee may previously by notice to the other Party have
stipulated). Notices shall be deemed to be given in the case of a facsimile transmission when sent
provided it is confirmed by international courier sent not later than the next business day and in
the case of international courier upon receipt by the other Party.

          7.7 Finder’s Fee. Each party agrees to indemnify and to hold harmless the other party
from any liability for any commission or compensation in the nature of a finders’ fee (and the
costs and expenses of defending against such liability or asserted liability) for which the
indemnifying party or any of its officers, partners, employees or representatives is responsible.

          7.8 Expenses. Irrespective of whether the Closing is effected, each party shall pay
all costs and expenses that it incurs with respect to the negotiation, execution, delivery and
performance of this Agreement. If any action at law or in equity is necessary to enforce or
interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable
attorney’s fees, costs and necessary disbursements in addition to any other relief to which such
party may be entitled.

          7.9 Amendments and Waivers. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular
instance and either retroactively or prospectively but only if so expressly stated), only with the
written consent of the Company and Investor. Any amendment or waiver effected in accordance with
this paragraph shall be binding upon each holder of any securities purchased under this Agreement
at the time outstanding, each future holder of all such securities, and the Company.

          7.10 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision shall be excluded

 

 

from this Agreement and the balance of the Agreement shall be interpreted as if such
provisions were so excluded and shall be enforceable in accordance with its terms.

          7.11 Entire Agreement. This Agreement and the documents referred to herein
constitute the entire agreement among the parties and no party shall be liable or bound to any
other party regarding the subject matter hereof and thereof in any manner by any warranties,
representations, or covenants except as specifically set forth herein or therein.

          7.12 Replacement of Securities. If any certificate or instrument evidencing any
Shares is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in
exchange and substitution for and upon cancellation thereof, or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction and the execution by the holder
thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and
hold harmless the Company for any losses in connection therewith, including a customary and
reasonable bond, if requested. The applicants for a new certificate or instrument under such
circumstances shall also pay any reasonable third-party costs associated with the issuance of such
replacement Shares.

          7.13 Adjustments in Share Numbers and Prices. In the event of any stock split,
subdivision, dividend or distribution payable in shares of Common Stock (or other securities or
rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the date
hereof, each reference in this Agreement to a number of shares or a price per share shall be
amended to appropriately account for such event.

[Remainder of This Page Intentionally Left Blank]

 

 

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written.

	 	 	 	 	 
	The Company:

Santarus, Inc.

 	 	 
	By:  	/s/ Giuseppe Cipriano
 	 	 
	 	Title: CEO 	 	 
	 	 	 	 
	 
	Investor:

Cosmo Technologies Limited

 	 	 
	By:  	/s/ Gerald T. Proehl
 	 	 
	 	Title: President and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]